PolyPeptide Group AGPLYGF 56 PB Ratio is 3.56 as of Jul. 05, 2026, which is 36% above its 10-year median of 2.61. GuruFocus rates PLYGF with a GF Score™ of 56/100 and a GF Value™ of $26.83 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 920 Drug Manufacturers companies, PolyPeptide Group AG ranks worse than 82.72% on this metric.
PolyPeptide Group AG stock PB Ratio (=5.13) is close to 3-year high of 5.13.
The historical rank and industry rank for PolyPeptide Group AG's PB Ratio or its related term are showing as below:
PLYGF'
s PB Ratio Range Over the Past 10 Years
Min: 1.3 Med: 2.61 Max: 24.15
Current: 5.13
During the past 8 years, PolyPeptide Group AG's highest PB Ratio was 24.15. The lowest was 1.30. And the median was 2.61.
PLYGF's PB Ratio is ranked worse than 82.72% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.92
vs PLYGF: 5.13
During the past 12 months, PolyPeptide Group AG's average Book Value Per Share Growth Rate was -4.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.60% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of PolyPeptide Group AG was 37.90% per year. The lowest was -8.70% per year. And the median was 23.30% per year.
Back to Basics: PB Ratio
PolyPeptide Group AG (OTCPK:PLYGF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
PolyPeptide Group AG PB Ratio Related Terms
PolyPeptide Group AG PB Ratio Historical Data
* Premium members only.
The historical data trend for PolyPeptide Group AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
PolyPeptide Group AG (PLYGF) has a PB Ratio of 3.56 as of Jul. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PolyPeptide Group AG and its competitors. This is 36% above median its historical median of 2.61. Over the past decade, PolyPeptide Group AG's PB Ratio has ranged from 1.30 to 24.15. According to the industry distribution chart, PolyPeptide Group AG ranks #761 out of 920 companies in the Drug Manufacturers industry, placing it in the top 82.7%.
Is PolyPeptide Group AG's PB Ratio too high?
PolyPeptide Group AG's current PB Ratio of 3.56 is 36% above median its 10-year median of 2.61. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 24.15. The Drug Manufacturers industry median PB Ratio is 1.92. PolyPeptide Group AG's value of 3.56 is 85.4% above this industry median. Based on the distribution chart, PolyPeptide Group AG ranks #761 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PolyPeptide Group AG has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PolyPeptide Group AG ranks #761 out of 920 companies for PB Ratio. This places PolyPeptide Group AG in the lower half of its industry. The industry median PB Ratio is 1.92. PolyPeptide Group AG's value of 3.56 is 85.4% above this benchmark. Historically, PolyPeptide Group AG's own PB Ratio has ranged from 1.30 to 24.15 over the past decade. While the company's 10-year median is 2.61 vs. the industry median of 1.92, PolyPeptide Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.92, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PolyPeptide Group AG's current PB Ratio of 3.56 is 85.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PolyPeptide Group AG and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PolyPeptide Group AG's current PB Ratio is 3.56, which is 36% above median its own 10-year median of 2.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $26.83, compared to a current price of $43.00 — trading 60.3% above its estimated fair value. The current PB Ratio is 3.56, which is 36% above median its 10-year median of 2.61 and 85.4% above the Drug Manufacturers industry median of 1.92. PolyPeptide Group AG's overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current PB Ratio is 3.56 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of $43.00 is trading 60.3% above its estimated GF Value™ of $26.83.
GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.
Key valuation signals for PLYGF:
PB Ratio: 3.56 (36% above median its 10-year median of 2.61)
GF Value™: $26.83 vs. price of $43.00 (60.3% above fair value)
Industry Position: 85.4% above the Drug Manufacturers median (#761 of 920)
No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
56GF Score
Get the complete analysis for PLYGF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLYGF has been successfully added to your 
